Calidi Biotherapeutics Announces Issuance Of New US Patent Covering Novel SuperNova Technology Platform
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics has been granted a new US patent for its SuperNova Technology Platform, which is a significant development for the company's proprietary technology and intellectual property portfolio.
November 20, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The issuance of a new US patent for Calidi Biotherapeutics' SuperNova Technology Platform represents a strengthening of the company's intellectual property and may positively influence investor perception.
The grant of a new patent typically protects a company's technology from competition and can be seen as a validation of the company's research and development efforts. This can lead to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100